You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.

Resource Center

Explore the clinical and patient materials for our PAH therapies—Orenitram, TYVASO, and Remodulin—as well as additional PAH information and tools in the Resource Center below.

By selecting “Add to my Request Form,” you can add materials to your Resource Center Request Form and they will be delivered to your practice, as well as get in contact with a United Therapeutics Representative.

After you have made your selection, click the REQUEST NOW button below, which will take you to the form with your materials you have chosen.

Request Now



Orenitram® resources


  • Orenitram Patient Brochure: Considering Orenitram thumbnail

    Orenitram Patient Brochure: Considering Orenitram

    A guide for patients considering Orenitram to learn why treatment may be right for them and more.

    DOWNLOAD
  • Orenitram Patient Brochure: What to Expect thumbnail

    Orenitram Patient Brochure: What to Expect

    A guide for patients to learn what to expect between the time they are prescribed Orenitram and when they receive their first shipment of drug.

    DOWNLOAD
  • Orenitram Patient Brochure: Getting Started thumbnail

    Orenitram Patient Brochure: Getting Started

    An informative brochure highlighting 3 key steps to successfully get patients started on Orenitram.

    DOWNLOAD
  • Orenitram HCP and Patient Package: 90-Day Trial Program thumbnail

    Orenitram HCP and Patient Package: 90-Day Trial Program

    An informational package initiating patients in a 90-day trial of Orenitram treatment.

    DOWNLOAD
  • Orenitram HCP and Patient Package: Side Effect Management thumbnail

    Orenitram HCP and Patient Package: Side Effect Management

    Brochures for healthcare providers and patients to learn more about Orenitram side effects and the best strategies to manage them.

    DOWNLOAD
  • Orenitram HCP Referral Form thumbnail

    Orenitram HCP Referral Form

    A referral form and 3-step process to authorize patients to receive Orenitram from their Specialty Pharmacy.

    DOWNLOAD

TYVASO® resources


  • TYVASO Patient Brochure thumbnail

    TYVASO Patient Brochure

    Informational brochure for patients that provides details on PAH, treatment, administration tips, and more.

    DOWNLOAD
  • TYVASO Patient Video: How to Use TYVASO thumbnail

    TYVASO Patient Video: How to Use TYVASO

    Helping patients learn how to assemble, use, and clean their device, and discover user-friendly enhancements that facilitate ease of use.

    WATCH
  • TYVASO Patient Instructions for Use thumbnail

    TYVASO Patient Instructions for Use

    TYVASO Instructions for Use manual with details on programming, safety, cleaning, and storage.

    DOWNLOAD
  • TYVASO HCP Referral Form thumbnail

    TYVASO HCP Referral Form

    A referral form for HCPs outlining a 6-step process to ensure patients receive TYVASO treatment.

    DOWNLOAD

Remodulin® resources


  • Remodulin HCP DAW State Language thumbnail

    Remodulin HCP DAW State Language

    Outlines state-specific requirements for “Dispense as Written” (DAW) to prescribe brand name Remodulin.

    DOWNLOAD
  • Remodulin HCP Referral Form thumbnail

    Remodulin HCP Referral Form

    A referral form to fill out for patients to receive Remodulin or TYVASO through Specialty Pharmacies.

    DOWNLOAD
  • Remodulin Patient Video: How Blood Flows in the Vessels in the Lungs thumbnail

    Remodulin Patient Video: How Blood Flows in the Vessels in the Lungs

    See what happens to the flow of blood in your lungs with PAH.

    WATCH
  • Remodulin Patient Video: Carey’s Story thumbnail

    Remodulin Patient Video: Carey’s Story

    PAH patient Carey shares her story about how she persevered and didn’t let her disease define her.

    WATCH
  • Remodulin Patient Video: Donna’s Story—Remodulin Injection IV thumbnail

    Remodulin Patient Video: Donna’s Story—Remodulin Injection IV

    Donna discusses PAH obstacles and treatment with Remodulin IV, which inspired her to become a nurse.

    WATCH
  • Remodulin Patient Video: Helpful Information About Remodulin thumbnail

    Remodulin Patient Video: Helpful Information About Remodulin

    Dr. Sean Studer and nurse Glenna Traiger review Remodulin benefits, risks, administration, and side effects.

    WATCH
  • Remodulin Patient Video: Living With Remodulin thumbnail

    Remodulin Patient Video: Living With Remodulin

    Errin and Donna discuss their experiences with Remodulin IV and SC and what has changed since diagnosis.

    WATCH
  • Remodulin Patient Video: PAH Life Hacks—Showering With Your Pump thumbnail

    Remodulin Patient Video: PAH Life Hacks—Showering With Your Pump

    PAH patient Carey shares her tips on how to protect a pump in the shower.

    WATCH
  • Remodulin Patient Video: PAH Life Hacks—Traveling With Your Pump thumbnail

    Remodulin Patient Video: PAH Life Hacks—Traveling With Your Pump

    PAH patient Wendy shares her advice that made traveling with a Remodulin pump more manageable for her.

    WATCH
  • Remunity HCP and Patient Video: Remunity User Guide—First-Time Setup thumbnail

    Remunity HCP and Patient Video: Remunity® User Guide—First-Time Setup

    A video on setting up the Remunity pump, including pairing pump to remote and setting a delivery rate.

    WATCH
  • Remunity HCP and Patient Video: Remunity User Guide—Connecting Your First Cassette thumbnail

    Remunity HCP and Patient Video: Remunity® User Guide—Connecting Your First Cassette

    A video on how to prime a Remodulin cassette, connect it to the pump, and connect the pump to the catheter.

    WATCH
  • Remunity HCP and Patient Video: Remunity User Guide—Cassette Change thumbnail

    Remunity HCP and Patient Video: Remunity® User Guide—Cassette Change

    A video on how to disconnect infusion sets before changing a cassette, replace the pump battery, and reconnect devices.

    WATCH
  • Remunity HCP and Patient Video: Remunity User Guide—Pump Alerts and Alarms thumbnail

    Remunity HCP and Patient Video: Remunity® User Guide—Pump Alerts and Alarms

    A video showing what Remunity pump notifications, alerts, and alarms mean and what to do when they occur.

    WATCH
  • Remunity HCP and Patient Video: Remunity User Guide—Troubleshooting and FAQs thumbnail

    Remunity HCP and Patient Video: Remunity® User Guide—Troubleshooting and FAQs

    A video about how to troubleshoot if the pump isn’t functioning properly, including answers to frequently asked questions.

    WATCH
  • Remunity HCP and Patient Video: Remunity User Guide—Self-Filling a Remodulin Cassette thumbnail

    Remunity HCP and Patient Video: Remunity® User Guide—Self-Filling a Remodulin Cassette

    A video on how to self-fill a cassette from home with the help of a Specialty Pharmacy.

    WATCH
  • Remodulin HCP and Patient Video: Remodulin SC Site Pain thumbnail

    Remodulin HCP and Patient Video: Remodulin SC Site Pain

    Patients and HCPs talk about injection site pain with Remodulin SC and ways to help manage it.

    WATCH

PAH Management resources


  • PAH HCP Tool: REVEAL/ERS Risk Stratification and Calculator thumbnail

    PAH HCP Tool: REVEAL/ERS Risk Stratification and Calculator

    Resource for HCPs with REVEAL/ERS risk stratification education and copies of calculator templates.

    DOWNLOAD
  • PAH HCP Tool: REVEAL/ERS Calculator thumbnail

    PAH HCP Tool: REVEAL/ERS Calculator

    Resource for HCPs with copies of REVEAL/ERS calculator templates to help assess risk in patients with PAH.

    DOWNLOAD
  • PAH HCP Tool: Noninvasive/French Risk Stratification and Calculator thumbnail

    PAH HCP Tool: Noninvasive/French Risk Stratification and Calculator

    Resource for HCPs with risk stratification using French registry data and copies of calculator templates.

    DOWNLOAD
  • PAH HCP Tool: REVEAL Lite 2 Risk Calculator thumbnail

    PAH HCP Tool: REVEAL Lite 2 Risk Calculator

    Resource for HCPs to determine patient risk utilizing the REVEAL Lite 2 calculator.

    DOWNLOAD
  • PAH Patient Video: PAH Basics thumbnail

    PAH Patient Video: PAH Basics

    Dr. Lana Melendres-Groves, a PAH expert, explains PAH and provides details on the cardiovascular system.

    WATCH
  • PAH Patient Video: PAH Treatment Goals thumbnail

    PAH Patient Video: PAH Treatment Goals

    Dr. Lana Melendres-Groves describes treatment goals and how they can help assess if treatment is working well.

    WATCH
  • PAH Patient Video: PAH Treatment Options thumbnail

    PAH Patient Video: PAH Treatment Options

    Education on risk status, PAH medication classes, and treatment options with Dr. Lana Melendres-Groves.

    WATCH
  • PAH Patient Video: Understanding PAH thumbnail

    PAH Patient Video: Understanding PAH

    Explanation of how PAH affects the heart and lungs, how it progresses, and how treatments work within 3 key pathways.

    WATCH
  • PAH Patient Waiting Room Checklist thumbnail

    PAH Patient Waiting Room Checklist

    Questions and details patients with PAH should consider while preparing to visit their HCP.

    DOWNLOAD

ERS=European Respiratory Society; IV=intravenous; PAH=pulmonary arterial hypertension; PH=pulmonary hypertension; REVEAL=Registry to Evaluate Early and Long-Term PAH Disease Management; SC=subcutaneous.

This website uses cookies to ensure you get the best experience on our website. Learn more.

SELECTED IMPORTANT SAFETY INFORMATION

  • Orenitram is Contraindicated in patients with severe hepatic impairment (Child Pugh Class C).
  • Tyvaso has a Warning and Precaution for patients with low systemic arterial pressure, as Tyvaso may produce symptomatic hypotension.
  • Remodulin has a Warning and Precaution for chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter, as they are associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.

Please see below for Indication, Important Safety information, and links to the Full Prescribing Information for Orenitram, TYVASO, and Remodulin.

SELECTED IMPORTANT SAFETY INFORMATION

  • Orenitram is Contraindicated in patients with severe hepatic impairment (Child Pugh Class C).
  • Tyvaso has a Warning and Precaution for patients with low systemic arterial pressure, as Tyvaso may produce symptomatic hypotension.
  • Remodulin has a Warning and Precaution for chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter, as they are associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.

Please see below for Indication, Important Safety Information, and links to the Full Prescribing Information for Orenitram, TYVASO, and Remodulin.

Orenitram® (treprostinil) Extended-Release Tablets

INDICATION

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

IMPORTANT SAFETY INFORMATION FOR ORENITRAM

CONTRAINDICATIONS

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

WARNINGS AND PRECAUTIONS

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

ADVERSE REACTIONS

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

DRUG INTERACTIONS

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

SPECIFIC POPULATIONS

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

Please see Full Prescribing Information and Patient Information at orenitram.com or call 1-877-UNITHER (1-877-864-8437).

OREISIhcpOCT19

TYVASO® (treprostinil) Inhalation Solution

INDICATION

TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.

While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

IMPORTANT SAFETY INFORMATION FOR TYVASO

WARNINGS AND PRECAUTIONS

  • TYVASO is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, TYVASO may produce symptomatic hypotension.
  • TYVASO inhibits platelet aggregation and increases the risk of bleeding.
  • Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.

DRUG INTERACTIONS/SPECIFIC POPULATIONS

  • The concomitant use of TYVASO with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
  • Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8.
  • Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
  • Safety and effectiveness in pediatric patients have not been established.
  • Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD), 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.

ADVERSE REACTIONS

Pulmonary Arterial Hypertension (WHO Group 1)

In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥4% of patients were dizziness and diarrhea.

Please see Full Prescribing Information, the TD-100 and TD-300 TYVASO® Inhalation System Instructions for Use manuals, and other additional information at www.tyvaso.com or call 1-877-UNITHER (1-877-864-8437).

TYVISIhcpAPR2021(PAH)

Remodulin® (treprostinil) Injection

INDICATION

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

IMPORTANT SAFETY INFORMATION FOR REMODULIN

WARNINGS AND PRECAUTIONS

  • Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
  • Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
  • Titrate slowly in patients with hepatic or renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.
  • Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
  • Remodulin inhibits platelet aggregation and increases the risk of bleeding.

ADVERSE REACTIONS

  • In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema(9% vs. 3%), and hypotension (4% vs. 2%).

DRUG INTERACTIONS

  • Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

SPECIFIC POPULATIONS

  • In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
  • Safety and effectiveness of Remodulin in pediatric patients have not been established.
  • It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

REMISIhcpOct19